AstraZeneca enters weight-loss market with oral GLP-1 drug

Yahoo Finance published this video item, entitled “AstraZeneca enters weight-loss market with oral GLP-1 drug” – below is their description.

AstraZeneca (AZN) is re-entering the weight loss drug market through a new partnership with China’s Eccogene. The deal provides AstraZeneca with global rights, excluding China, to develop and commercialize Eccogene’s oral GLP-1 candidate for obesity management.
Under the terms, AstraZeneca will pay Eccogene $185 million upfront to license the drug, coming after AstraZeneca halted the development of two previous obesity medications this year due to disappointing trial results.
Yahoo Finance Health Reporter Anjalee Khemlani breaks down all the details, providing insights into the ongoing weight-loss drug race.
For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.
Subscribe to Yahoo Finance: https://yhoo.it/2fGu5Bb
#youtube #yahoofinance #astrazeneca
About Yahoo Finance:
At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.
Yahoo Finance Plus: With a subscription to Yahoo Finance Plus get the tools you need to invest with confidence. Discover new opportunities with expert research and investment ideas backed by technical and fundamental analysis. Optimize your trades with advanced portfolio insights, fundamental analysis, enhanced charting, and more.
To learn more about Yahoo Finance Plus please visit: https://yhoo.it/33jXYBp
Connect with Yahoo Finance:
Get the latest news: https://yhoo.it/2fGu5Bb
Find Yahoo Finance on Facebook: http://bit.ly/2A9u5Zq
Follow Yahoo Finance on Twitter: http://bit.ly/2LMgloP
Follow Yahoo Finance on Instagram: http://bit.ly/2LOpNYz
Follow Yahoo Finance Premium on Twitter: https://bit.ly/3hhcnmV
Yahoo Finance YouTube Channel